1,890,154 research outputs found
Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152
No full textPURPOSE: To determine the factors affecting trabeculectomy success.
DESIGN: Retrospective analysis of 2 randomized controlled trials comparing an antibody against transforming growth factor beta2 (TGF-beta2) with vehicle (placebo) for prevention of fibrosis after trabeculectomy, in which there was no significant difference between the treatment groups.
PARTICIPANTS: Data were from patients (n = 726) with a diagnosis of primary open-angle glaucoma, chronic angle-closure glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma (PG) who had an intraocular pressure (IOP) > 21 mmHg and visual field or optic disc changes characteristic of glaucoma and were taking the maximum tolerated dose of medication before trabeculectomy.
METHODS: Patients had trabeculectomy and 4 subconjunctival injections of a human monoclonal antibody to TGF-beta2 (CAT-152) or a placebo. The definition of trabeculectomy success in the protocols was an IOP between 6 and 16 mmHg inclusive at months 6 and 12. Analyses of success used factors identified by ophthalmic experts.
MAIN OUTCOMES MEASURES: Covariates analyzed included patient age, black race, gender, time since diagnosis, primary diagnosis, country, diabetes, mean defect, cup-to-disc (C/D) ratio, suture type, anesthetic, flap type, IOP at listing for surgery, suture release/lysis, needling, reformed anterior chamber, wound leak, severe bleb vascularity, and bleb microcysts.
RESULTS: A stepwise logistic regression model found the following predictors of treatment success: PG (odds ratio [OR], 4.11; 95% confidence interval [CI], 1.41-11.99), high C/D ratio (OR, 2.84; 95% CI, 1.15-6.99), and use of a corneal traction suture (OR, 1.67; 95% CI, 1.09-2.56). A negative relationship was found for black race (OR, 0.28; 95% CI, 0.13-0.62); treatment in France (OR, 0.35; 95% CI, 0.17-0.70), Sweden (OR, 0.17; 95% CI, 0.05-0.58), Spain (OR, 0.37; 95% CI, 0.21-0.68), Poland (OR, 0.53; 95% CI, 0.32-0.88), or Hungary (OR, 0.14; 95% CI, 0.06-0.34); and suture release/lysis (OR, 0.34; 95% CI, 0.22-0.53). The effect of needling was marginally statistically significant (OR, 0.56; 95% CI, 0.31-1.01).
CONCLUSIONS: Successful trabeculectomy outcome was associated with PG, higher C/D ratio, and corneal traction suturing. Factors associated with surgical failure were black race and suture release/lysis. Intercountry differences also were observed
SDS-PAGE analysis of site-specific fluorescent-labeled 059-152-Fv and 059-152-Fab.
No full textReducing and non-reducing SDS-PAGE analysis of 059-152-Fv (A) and 059-152-Fab (B). (lane 1) 059-152-Fv, (lane 2) AzF-incorporated 059-152-Fv, (lane 3) Alexa-488 conjugated 059-152-Fv, (lane 4) 059-152-Fab, (lane 5) AzF-incorporated 059-152-Fab, and (lane 6) Alexa-488 conjugated 059-152-Fab. Fluorescent images and CBB-stained images were acquired from the same gels.</p
Binding kinetics of 059-152-Fv and 059-152-Fab to the EGFR-ECD.
No full textBinding kinetics of 059-152-Fv and 059-152-Fab to the EGFR-ECD.</p
Az AN-152 (AEZS-108) célzott daganatterápiás készítmény hatásmechanizmusának vizsgálata
No full textAz uvealis melanomában szenvedő betegek mintegy felénél már a diagnózis felállításakor jelen van távoli áttét, a jelenleg alkalmazott szisztémás kezeléstől függetlenül ezen betegek mintegy 90%-át 2 éven belül elveszítjük. A célzott daganatterápiára kifejlesztett, doxorubicinnel konjugált LHRH (Luteinizing Hormon- Releasing Hormon) analóg AN-152 (AEZS-108) daganat proliferációra gyakorolt gátló hatását számos in vitro és in vivo kísérletben igazolták.Korábbi vizsgálataink szerint az OCM-3 uvealis melanoma sejtek overexpresszálják az LHRH receptorát és az in vitro AN-152 kezelés szignifikánsan csökkenti proliferációjukat. Jelenlegi munkánk során azt tanulmányozzuk, hogy az AN-152 milyen génexpressziós változásokat idéz elő OCM-3 sejtekben in vitro kezelés hatására. A kísérlet során real-time reverz transzkriptáz PCR array-t használtunk 94, az angiogenezisben részt vevő gén kvantitatív kifejeződésének vizsgálatára kezeletlen és AN-152-vel kezelt sejteken.Az upregulálódott gének közül a legjelentősebb változást a SERPINB5/Maspin tumorszupresszor génnél tapasztaltuk, míg a downregulált gének esetében a legkifejezettebb a daganatok progressziójában központi szerepű HIF1-α gén változása volt.Az említett gének fehérje szintű megjelenését Western blot analízissel is kiegészítettük.gjBiotechnológiaMSc/M
SDS-PAGE analysis of cell-free synthesized 059-152-Fv and 059-152-Fab.
No full text(A) 059-152-Fv was synthesized under a series of different concentrations (0, 0.2, and 0.4 mg/ml) of DsbC, as indicated. Total (T) and soluble (S) fractions of the internal solution were analyzed by reducing SDS-PAGE. (B) Purified 059-152-Fv was analyzed by reducing and non-reducing SDS-PAGE. The yields (mg per 1 ml internal solution) of partially purified Fv are indicated under each lane of the non-reducing SDS polyacrylamide gel image. (C) 059-152-Fab was synthesized in the presence of 0, 0.2, 0.4, and 0.8 mg/ml of DsbC, as indicated. (D) Purified 059-152-Fab was analyzed by reducing and non-reducing SDS-PAGE. The yields (mg per 1 ml internal solution) of partially purified Fab are indicated under each lane of the non-reducing SDS polyacrylamide gel image. BG: cell-free synthesis without template DNA. VH: cell-free synthesis of VH without DsbC. VL: cell-free synthesis of VL without DsbC. VHCH1: cell-free synthesis of VHCH1 without DsbC. L chain: cell-free synthesis of light chain without DsbC. Gels were stained with CBB.</p
C-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDAD
No full textC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADjp
C-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDAD
No full textC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADjp
C-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDAD
No full textC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADjp
C-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDAD
No full textC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADPD
C-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDAD
No full textC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADC-152 URGENTE UNA FORMACIÓN DE PROFESIONALES CON UN APASIONADO COMPROMISO CON LA SOCIEDADjp
- …
